We observed that Axl was constitutively phosphorylated (active) in CLL B-cells from all tested patients prior to ibrutinib therapy and this was maintained on the sequential samples of patients still on ibrutinib treatment (Figure 3A). Here, AXL is linked to B-cell chronic lymphocytic leukemia.